Preview

Rational Pharmacotherapy in Cardiology

Advanced search

WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY

https://doi.org/10.20996/1819-6446-2018-14-2-229-234

Full Text:

Abstract

Aim. To study the awareness and opinion of patients with atrial fibrillation (AF) about the stroke prevention.

Material and methods. This study based on the questionnaire survey of 544 patients from three regions of Russia is the third part of the PRIMA-TERRA register. The survey was carried out in the period from 01.12.2012 to 01.07.2013 by independent employees on a special questionnaire of 9 questions. The ratio of men and women was 42% vs 58%, respectively, the average age was 65.6Ѓ}8.2 years. The AF duration was 7.6Ѓ}2.0 years. The average score of CHA2DS2-VASc was 3.4Ѓ}1.4.

Results. Less than 70% of patients were informed of possible AF complications, of which less than a third – about the risk of stroke. Only 62% of patients believed that they take drugs for the stroke prevention, of which only 31% took warfarin, 15% new oral anticoagulants (NOAC). The majority of patients received antiplatelet agents and their combinations – medications not recommended for this purpose by modern National and European cardiology guidelines. Less than 60% of the respondents were informed about the NOACs, while clinically significant information about the benefits of this group of drugs was provided by doctors only to 18% of patients. The main reason limiting the widespread use of NOACs is the high cost of these drugs.

Conclusion. Awareness of patients about AF thromboembolic complications is extremely inadequate. For the prevention of stroke, most patients take antiplatelet agents and their combinations, less than a half – anticoagulants. The main reason for refusing to receive the NOACs is the high cost of this group of drugs.

About the Authors

R. М. Linchak
National Research Center for Preventive Medicine
Russian Federation

Ruslan M. Linchak – MD, PhD, Associate Professor, Deputy Director

Petroverigsky per. 10, Moscow, 101990



O. G. Kompaniyets
Kuban State Medical University
Russian Federation

Olga G. Kompaniyets – MD, PhD, Assistant, Chair of Clinical Pharmacology and Functional Diagnostics

Sedina ul. 4, Krasnodar, 350063



A. M. Nedbaykin
Bryansk Cardiologic Dispensary
Russian Federation

Andrei M. Nedbaykin – MD, PhD, Head Physician

Oktyabrskaya ul. 44, Bryansk, 241050



References

1. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18(11):1609-78. doi:10.1016/j.rec.2016.11.033

2. Saal K, Hoffmann B, Blauth E et al. Analysis of the process of oral anti-coagulation therapy for the identification of safety problems in primary care. Z Allg Med. 2009;85:148-55.

3. Wyse D.G. Bleeding while starting anticoagulation for thromboembolism prophylaxis in elderly patients with atrial fibrillation. Circulation. 2007;115:2684-86. doi:10.1161/CIRCULATIONAHA.107.704122.

4. Chenot J.F., Hua T.D., Abed M.A. et al. Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. BMC Family Practice. 2014;15:104-12.

5. Linchak RM, Kompaniets OG, Nedbaykin AM et al. What do doctors think and know about antithrombotic therapy in atrial fibrillation? Cardiologiia. 2014;10:32-8. (In Russ.)

6. Protasov K.V., Fedorishina O.V. Realities and prospects of stroke prevention in atrial fibrillation: an analysis of the opinion of doctors. Cardiologiia. 2013;10:30-6. (in Russ.)

7. Boytsov SA, Yakushin SS, Martsevich S.Yu. et al. Outpatient and polyclinic register of cardiovascular diseases in the Ryazan region (REQUAS): the main tasks, the experience of creation and the first results. Rational Pharmacotherapy in Cardiology. 2013;9(1):4-14. (in Russ.)

8. Linchak RM, Kompaniets OG, Nedbaykin AM, et al. What are the realities of prescribing and controlling antithrombotic therapy in atrial fibrillation in outpatient practice? Cardiologiia. 2015;55(6):34-9. (In Russ.)

9. Madrid A.H., Potpara T.S., Dagres N. et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace 2016;18(3):463-7. doi:10.1093/europace/euv448.

10. Amara W., Larsen T.B., Sciaraffia E. et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace 2016;18(1):151-5.

11. Gilyarov M. Yu., Sulimov V.A. Antithrombotic therapy in atrial fibrillation: old problems and new solutions. Rational Pharmacotherapy in Cardiology. 2010;6 (1): 85-89. (In Russ.)

12. Lip G., Bassand J-P., Fitzmaurice D. et al. Inappropriate utilization of anticoagulation in patients with atrial fibrillation: the global anticoagulant registry in the field (GARFIELD) registry. J Am Coll Cardiol. 2012;59 (13s1):E670.

13. Korneva E.V., Rachina S.A., Milyagin V.A. Prevention of thromboembolism in patients with atrial fibrillation in the outpatient practice of Smolensk. Klinicheskaja Farmakologija i Terapija. 2005;4:1212. (In Russ.)

14. Huisman M.V. Results of the 1st Phase of the Internetional GLORIA-AF Registry Programm: Regional Treatment Differences Before the Era of Novel Anticoagulants. Oral Presentation on 7 May 2014 at the World Congress of Cardiology Scientific Sessions 2014, Melbourne, Australia.

15. Camm A.J., Accetta G., Ambrosio G. et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. GARFIELD-AF Investigators. Heart. 2017;103(4):307-14. doi:10.1136/heartjnl-2016-309832.

16. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210.

17. Panchenko EP, Akseta G., Libis R.A. and others. Characteristics of risk factors and prescribed antithrombotic therapy in patients with newly diagnosed non-valvular atrial fibrillation in the Russian Federation (according to the results of the international register GARFIELD-AF). Cardiologiia. 2017;57(4):38-45. (In Russ.) [

18. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P. The experience of studying atrial fibrillation on the basis of the PROFILE register. Cardiovascular Therapy and Prevention. 2014;13(2):35-9. (In Russ.)

19. Petrov VI, Shatalova OV, Maslakov AS Analysis of antithrombotic therapy in patients with a constant form of atrial fibrillation (pharmacoepidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):174-7. (In Russ)

20. Potpara TS, Pison L, Larsen TB et al. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015;17: 468-472. doi:10.1093/europace/euv025.

21. Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1016/j.jacc.2013.07.093.

22. Connolly S., Ezekowitz M., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1093/europace/eux022.


For citation:


Linchak R.М., Kompaniyets O.G., Nedbaykin A.M. WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY. Rational Pharmacotherapy in Cardiology. 2018;14(2):229-234. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-2-229-234

Views: 180


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)